Chronic hepatitis B virus (HBV) infection is a major global health problem. Current antiviral therapy including pegylated interferon and nucleos(t)ide analogue is effective in reducing progression to cirrhosis, hepatic decompensation, and hepatocellular carcinoma but the rate of HBsAg seroclearance is ...
Hepatitis B virus (HBV) is a major cause of acute and chronic liver disease and represents a major public health problem worldwide. Current antiviral therapies with nucleos(t)ide analogues can effectively suppressing viremia but are not curative, and have little or no impact upon the HBV cccDNA...
Chronic hepatitis B (CHB), caused by hepatitis B virus (HBV), is a major cause of advanced liver disease and hepatocellular carcinoma (HCC) worldwide. HBV
end-stage liver disease or hepatocellular carcinoma.China has the largest burden of HBV in the world,with approximately 70 million HBV carriers,of which 20e30 million are chronic hepatitis B(CHB)patients.2,3 As the developme...
Results from the REP 301 and REP 401 studies showed combination therapy with REP2139 and pegylated interferon led to high rates of hepatitis B seroconversion in patients coinfected with hepatitis B and hepatitis D with more than half of treated patients also achi...
Therapeutic goal of chronic hepatitis B is a “functional” cure of HBV infection, which is rarely achieved with currently available antiviral agents. Major obstacles to a functional cure are intricate stability of HBV cccDNA and dysfunctional anti-HBV immune response. Antiviral and immunotherapeutic st...
Treatment of chronic hepatitis B virus (HBV) infection with the viral DNA polymerase inhibitors or pegylated alpha-interferon has led to a significant retardation in HBV-related disease progression and reduction in mortality related to chronic hepatitis B associated liver decompensation and hepatocellular ...
Prevention of hepatitis B virus infection by vaccination has been successful but although it has reduced the incidence of new infections in the USA and in other parts of the world (Buckley and Strom, 2016), there are still at least 250 million chronically infected individuals, for whom the vac...
Among the factors influencing relapse after clinical cure of chronic hepatitis B(CHB). There is no standardization of baseline HBsAg levels and end-of-treatment HBsAb levels. This multicenter, retrospective study enrolled 136 patients who achieved functional cure from June 2019 to December 2023, and...
Ascletis Pharma Inc. announces the poster presentation of ASC42, a novel farnesoid X receptor agonist, in combination with PEGylated interferon and entecavir in chronic hepatitis B patients with 12-week treatment at European Associa...